Selenium Nanoparticles in Atherosclerosis and Non-Alcoholic Fatty Liver Disease: A Comprehensive Review of Therapeutic Mechanisms, Targeted Delivery, and Translational Prospects
International Journal of Nanomedicine · 2026-10 · Volume 21 · 1-20
DOI: 10.2147/ijn.s637621 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2026-10. Verfasst von Keqian Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Xiangtan Central Hospital (The Affiliated Hospital of Hunan University), Xiangtan, Hunan, People's Republic of China. Hauptthemen laut MEDLINE: Atherosclerosis, Selenium, Non-alcoholic Fatty Liver Disease, Nanoparticles. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Selenium nanoparticles (SeNPs) have emerged as a promising nanomaterial in biomedicine due to their unique physicochemical properties. This review summarizes the research and progress of SeNPs in atherosclerosis (AS) and non-alcoholic fatty liver disease (NAFLD). In the AS model, CS-SeNPs (40 μg Se/kg/day, 10 weeks) significantly reduced the area of aortic plaques (25.1%). Similarly, PM@Se/Rb1 NPs significantly reduced the plaque area of the aortic arch (85→20%) and aortic root (79→26.5%). In the NAFLD model, various SeNPs improved the area of steatosis, reduced the levels of TC, TG, ALT, and AST, and inhibited inflammation, oxidative stress, and the progression of fibrosis. Unlike previous reviews that focus on a single disease, this review uniquely integrates and compares the therapeutic applications of SeNPs in AS and NAFLD by targeting their common pathological mechanisms. Additionally, we highlight conflicting findings on long-term safety and provide a comparative analysis of different stabilizer formulations. The limitations of the currently available evidence are predominantly derived from cell culture and animal models. Despite encouraging preclinical results, challenges remain regarding long-term safety, optimal stabilizer selection, and translational feasibility. Future directions should prioritize toxicological profiling, large-animal validation, and fibrosis-reversal efficacy to facilitate clinical translation of SeNPs as multi-target nanotherapeutics for chronic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Xiangtan Central Hospital (The Affiliated Hospital of Hunan University), Xiangtan, Hunan, People's Republic of China.
- Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan, People's Republic of China.
ORCID-Profile: Keqian Chen
Zitieren
APA
Chen, K., & Wang, S. Z. (2026). Selenium Nanoparticles in Atherosclerosis and Non-Alcoholic Fatty Liver Disease: A Comprehensive Review of Therapeutic Mechanisms, Targeted Delivery, and Translational Prospects. International Journal of Nanomedicine, Volume 21, 1-20. https://doi.org/10.2147/ijn.s637621
Vancouver
Chen K, Wang SZ. Selenium Nanoparticles in Atherosclerosis and Non-Alcoholic Fatty Liver Disease: A Comprehensive Review of Therapeutic Mechanisms, Targeted Delivery, and Translational Prospects. International Journal of Nanomedicine. 2026;Volume 21:1-20. doi:10.2147/ijn.s637621
BibTeX
@article{Chen2026,
author = {Chen, Keqian and Wang, Shu-Zhi},
title = {Selenium Nanoparticles in Atherosclerosis and Non-Alcoholic Fatty Liver Disease: A Comprehensive Review of Therapeutic Mechanisms, Targeted Delivery, and Translational Prospects},
journal = {International Journal of Nanomedicine},
year = {2026},
volume = {Volume 21},
pages = {1--20},
doi = {10.2147/ijn.s637621}
}
EUVIMED